In the conclusion of this Exclusive Interview, Scott Abbott talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about the patient response to the V-Go system.
Scott Abbott is the Director of Medical Development at Valeritas.
Transcript of this video segment:
Steve: What has been the response from the older population?
Scott Abbott: It’s been quite good. The fact that you can remove the burden of multiple injections and you can have this device on you and use it. I believe the numbers are over 40% of our patients are 65 years and older. It is actually under the Medicare part D as a drug benefit. So that is a huge help there. Most patients, I think over 90% of the patients, go to their pharmacy to get V-Go so they can get their V-Go with their insulins. So that’s a nice thing we have there.
Steve: Can they fill these early?
Scott Abbott: Yes, they would have to adhere to whatever the insulin is being used, the number of days you use prefill according to the insulin label. We can’t surpass the insulin label that’s approved, but it’d be on par with what is approved with those insulins.
Steve: Have you sold this any nursing homes?
Scott Abbott: It has been used in nursing homes. In fact I was the author of a publication that came out earlier this year. We did a small study in cooperation with a nursing home and found data that was quite beneficial in those patients. We found it contributed to better time in range, which is a term that describes when your glucose is in the 100-200 mg/dL range. We found that there was more time spent there. There was also a pretty significant reduction in nursing home time and therefore cost when using V-Go versus standard injections in the nursing home.
Steve: Is this available overseas?
Scott Abbott: It is not, it is only available currently in the United States. We have our marks in Europe so there is the possibility to go beyond the United States, but right now it’s only available in the United States.